The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Efficacy and safety of a proposed omalizumab biosimilar compared to the reference product in the management of uncontrolled moderate-to-severe allergic asthma: a multicenter, phase III, randomized, double-blind, equivalency clinical trial
|
|---|---|
| Published in |
Frontiers in immunology, July 2024
|
| DOI | 10.3389/fimmu.2024.1425906 |
| Pubmed ID | |
| Authors |
Mostafa Ghanei, Babak Ghalebaghi, Ramin Sami, Mehdi Torabizadeh, Majid Mirsadraee, Babak Amra, Marzieh Tavakol, Hanieh Raji, Morteza Fallahpour, Arda Kiani, Atefeh Abedini, Farahzad Jabbari Azad, Seyed Alireza Mahdaviani, Davood Attaran, Mohammad Samet, Sasan Tavana, Maryam Haddadzadeh shoushtari, Javad Nazari, FatemehAlsadat AghaeiMeybodi, Mohammad Reza Fazlollahi, Ramin Ghasemi, Araz Sabzvari, Hamidreza Kafi, Esmaeil Idani |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 2 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 1 | 50% |
| Other | 1 | 50% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 1 | 50% |
| Engineering | 1 | 50% |
Attention Score in Context
This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 September 2024.
All research outputs
#2,315,649
of 26,567,854 outputs
Outputs from Frontiers in immunology
#2,315
of 33,386 outputs
Outputs of similar age
#21,762
of 243,815 outputs
Outputs of similar age from Frontiers in immunology
#17
of 572 outputs
Altmetric has tracked 26,567,854 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 33,386 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.6. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 243,815 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 572 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.